The global smoking cessation market is going from strength to strength, globally, with ever increasing products coming to the market both prescription and over-the-counter (OTC). Most notable are the range of Vaping (e-cigarettes/smokeless cigarettes) products, a market which was estimated to be worth over $3 billion across both 2013 and 2014. So, where has this market come from?
Smoking patterns have shifted with many smokers quitting, or attempting to quit.
Prevalence of US Adult (18+) Smokers (%)
GMR Data / CDC 2015
As we can see from the table above, the amount of adult Americans that smoke has reduced significantly from 25.5% in 1990 to 17.8% by the end of this year; that’s 46.3 million (1990) to 36.5 million (2015). So, the number of smokers, in the US, has reduced by around 10 million in 25 years.
The US health authority – the Centers for Disease Control & Prevention (CDC) – indicate that the percentage of adult (daily) cigarette smokers who stopped smoking for more than one day in 2010, because they were trying to quit, was 42.7% of all adult smokers. The percentages for other age ranges are as follows:
- 48.5% of smokers aged 18–24 years
- 46.8% of smokers aged 25–44 years
- 38.8% of smokers aged 45–64 years
- 34.6% of smokers aged 65 years or older
In terms of smoking cessation, what we have is two distinct groups of people:
- Those that want to quit and have been succesful
- Those that want to quit and have failed (so far)
Both of these groups offer value to the smoking cessation market particularly the latter as they are recurrent users of smoking cessation products. Nicoderm and Habitrol are the primary Nicotine Replacement Therapy (NRT) products on the market, accounting for over 80% of the global NRT market revenue in 2013. Bupropion and Varenicline are the major products in the prescription drug segment of the smoking cessation market.
GMR Data’s smoking cessation report outlines the key factors affecting the market to 2023. GMR Data estimates that the global e-cigarette market will reach $15 billion by 2023. The report breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present, examining the key prescription and OTC drugs that drive the market. In addition to this crucial information, the report offers analysis and opinion on current R&D in the smoking cessation sector alongside in-depth analysis of the emerging, global e-cigarette market. The report also includes three exclusive interview transcripts from representatives from GlaxoSmithKline, Elder Pharma and Pfizer.
For more details on the pharmaceutical reports from GMR Data, browse their collection of reports. Or, to learn more about the smoking cessation market, check out GMR Data's full report.
Editor's Note:
This post was written by Simeon Pinder, Senior Analyst at GMR Data.
About GMR Data
GMR Data is an independent, business information research company. They were founded on the core principles of independence, financial and market accuracy, plus developing innovative business critical topics. GMR's dedicated, qualified analysts, researchers and writers produce up to date, quantifiable information which allows the company to produce accurate, forward facing reports across a variety of business sectors.
